GenSci 120
Alternative Names: GenSci-120Latest Information Update: 01 Sep 2025
At a glance
- Originator GeneScience Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Irritable bowel syndrome therapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- Preclinical Inflammatory bowel diseases; Rheumatoid arthritis; Sjogren's syndrome
Most Recent Events
- 01 Aug 2025 Changchun GeneScience Pharmaceutical initiates phase I clinical trials in heathy adult volunteers in China (SC) (NCT07040930)
- 21 Feb 2025 Preclinical trials in Autoimmune disorders in China (SC), prior to February 2025
- 21 Feb 2025 Preclinical trials in Inflammatory bowel diseases in China (SC), prior to February 2025